Severe community-acquired pneumonia treated with β-lactam-respiratory quinolone vs. β-lactam-macrolide combination

Acta Anaesthesiologica Scandinavica

Volumn 57, Issue 5, 2013, Pages 587-593

  Karhu, J ^a   Ala Kokko, T I ^a   Ohtonen, P ^a   Syrjala H ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFUROXIME; CEPHALOSPORIN; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC THERAPY; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BLOOD CULTURE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; FEMALE; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPTIC SHOCK; SPUTUM CULTURE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MACROLIDES; MALE; MIDDLE AGED; PNEUMONIA; QUINOLONES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84876289809     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/aas.12081     Document Type: Article

References (31)

1. Macfarlane J. Lower respiratory tract infection and pneumonia in the community. Semin Respir Infect 1999; 14: 151-62.
2. de Castro FR, Torres A. Optimizing treatment outcomes in severe community acquired pneumonia. Am J Respir Med 2003; 2: 39-54.
3. Mandell L, Wunderink R, Anzueto A, Bartlett J, Campbell G, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG. Infectious Disease Society of America/American Thoracic Society Consensus Guidelines on the management of community acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27-S72.
4. Angus DC, Marrie TJ, Obrosky S, Clermont G, Dremsizov TT, Coley C, Fine MJ, Singer DE, Kapoor WN. Severe community-acquired pneumonia; use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med 2002; 166: 717-23.
5. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, Kapoor WN. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275: 134-41.
6. Woodhead M, Welch CA, Harrison DA, Bellingan G, Ayres JG. Community-acquired pneumonia in the intensive care unit: secondary analysis of 17, 869 cases in the ICNARC Case Mix Programme Database. Crit Care 2006; 10: S1.
7. Karhu J, Ala-Kokko TI, Ylipalosaari P, Ohtonen P, Laurila JJ, Syrjälä H. Hospital and long-term outcomes of ICU-treated severe community-and hospital-acquired, and ventilator-associated pneumonia patients. Acta Anaesthesiol Scand 2011; 55: 1254-60.
8. Baddour L, Yu V, Klugman K, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, Chedid MB, Hui DS, Andremont A, Chiou CC, International Pneumococ-cal Study Group. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Care Med 2004; 170: 440-44.
9. Rodriguez A, Mendia A, Sirvent J-M, Barcenilla F, de la Torre-Brados M, Sole-Violan J, Rello J. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007; 35: 1493-98.
10. Martin-Loeches I, Lisboa T, Rodriguez A, Putensen C, Annane D, Garnacho-Montero J, Restrepo MI, Rello J. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010; 36: 612-20.
11. Caballero J, Rello J. Combination of antibiotic therapy in community-acquired pneumonia. Ann Intensive Care 2011; 1: 48.
12. Knaus W, Draper E, Wagner D, Zimmerman J. APACHE II: a severity of disease classification system. Crit Care Med 1985; 10: 818-29.
13. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter P, Thijs L. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22: 707-10.
14. Rello J, Rodriguez A, Lisboa T, Gallego M, Lujan M, Wun-derink R. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med 2009; 37: 456-62.
15. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-56.
16. Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-82.
17. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004; 164: 637-44.
18. Houck PM, Bratzler DW. Administration of first hospital antibiotics for community-acquired pneumonia: does timeliness affect outcomes? Curr Opin Infect Dis 2005; 18: 151-56.
19. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96.
20. Puskarich MA, Trzeciak S, Shapiro NI, Arnold RC, Horton JM, Studnek JR, Kline JA, Jones AE. (EMSHOCKNET). Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol. Crit Care Med 2011; 39: 2066-71.
21. Simonetti A, Viasus D, Garcia-Vidal C, Adamuz J, Roset A, Manresa F, Dorca J, Gudiol F, Carratala J. Timing of antibiotic administration and outcomes of hospitalized patients with community-acquired and health-care associated pneumonia. Clin Microbiol Infect 2012; 18: 1149-55.
22. Wilson BZ, Anzueto A, Restrepo MI, Pugh MJ, Mortensen EM. Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia. Crit Care Med 2012; 40: 2310-14.
23. Asadi L, Sligl WI, Eurich DT, Colmers IN, Tjosvold L, Marrie TJ, Majumdar SR. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2012; 55: 371-80.
24. Olive D, Hugues G, Devos P, Boussekey N, Chiche A, Meybeck A, Alfandari S, Leroy O. Severe pneumococcal pneumonia: impact of new quinolones on prognosis. BMC Infect Dis 2011; 11: 66.
25. Klepser ME, Ernst EJ, Petzold CR, Rhomberg P, Doern GV. Comparative bactericidal activities of ciprofloxacin, clina-floxacin, grepafloxacin, levofloxacin, moxifloxacin, and tro-vafloxacin against Streptococcus pneumoniae in a dynamic in vitro model. Antimicrob Agents Chemother 2001; 45: 673-78.
26. Gómez-Lus R, Adrián F, del Campo R, Gómez-Lus P, Sánchez S, García C, Rubio MC. Comparative in vitro bacte-riostatic and bactericidal activity of trovafloxacin, levo-floxacin and moxifloxacin against clinical and environmental isolates of Legionella spp. Int J Antimicrob Agents 2001; 18: 49-54.
27. File TM, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacine versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 1965-72.
28. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1999; 44: 835-38.
29. Amsden GW. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55: 10-21.
30. Dalhoff A, Shalit I. Immunomodulatory effects of quinolo-nes. Lancet Infect Dis 2003; 3: 359-71.
31. Zimmermann GS, Neurohr C, Villena-Hermoza H, Hatz R, Behr J. Anti-inflammatory effects of antibacterials on human bronchial epithelial cells. Respir Res 2009; 10: 89.